Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q424771> ?p ?o }
Showing triples 1 to 91 of
91
with 100 triples per page.
- Q424771 subject Q6973183.
- Q424771 subject Q7145095.
- Q424771 subject Q7335370.
- Q424771 subject Q8965786.
- Q424771 abstract "Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis published in the New England Journal of Medicine in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012.Despite rosiglitazone's effectiveness at decreasing blood sugar in type 2 diabetes mellitus, its use decreased dramatically as studies showed apparent associations with increased risks of heart attacks and death. Adverse effects alleged to be caused by rosiglitazone were the subject of over 13,000 lawsuits against GSK; as of July 2010, GSK had agreed to settlements on more than 11,500 of these suits.Some reviewers recommended rosiglitazone be taken off the market, but an FDA panel disagreed, and it remains available in the U.S. From November 2011 until November 2013, the federal government did not allow Avandia to be sold without a prescription from a certified doctor; moreover, patients were required to be informed of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies. In November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open label randomized control trial), which failed to show heart infarct risks associated with the drug.In Europe, the European Medicines Agency (EMA) recommended in September 2010 that the drug be suspended from the European market because the benefits of rosiglitazone no longer outweighed the risks. It was withdrawn from the market in the UK and India in 2010, and in New Zealand and South Africa in 2011.".
- Q424771 atcPrefix "A10".
- Q424771 atcSuffix "BG02".
- Q424771 bioavailability "99.0".
- Q424771 casNumber "122320-73-4".
- Q424771 chEBI "50122".
- Q424771 drugbank "DB00412".
- Q424771 fdaUniiCode "05V02F2KDG".
- Q424771 iupacName "(RS)-5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione".
- Q424771 pubchem "77999".
- Q424771 thumbnail Rosiglitazone.svg?width=300.
- Q424771 wikiPageExternalLink dpdirect.jsp?name=Rosiglitazone.
- Q424771 wikiPageExternalLink www.avandia.com.
- Q424771 wikiPageExternalLink ?ligand=BRL.
- Q424771 wikiPageExternalLink ?ligand=RGZ.
- Q424771 wikiPageExternalLink 483837.
- Q424771 wikiPageExternalLink a699023.html.
- Q424771 wikiPageWikiLink Q101991.
- Q424771 wikiPageWikiLink Q1053470.
- Q424771 wikiPageWikiLink Q1105202.
- Q424771 wikiPageWikiLink Q110739.
- Q424771 wikiPageWikiLink Q11081.
- Q424771 wikiPageWikiLink Q12152.
- Q424771 wikiPageWikiLink Q130146.
- Q424771 wikiPageWikiLink Q1393556.
- Q424771 wikiPageWikiLink Q1436668.
- Q424771 wikiPageWikiLink Q1477.
- Q424771 wikiPageWikiLink Q14890468.
- Q424771 wikiPageWikiLink Q14916190.
- Q424771 wikiPageWikiLink Q1813737.
- Q424771 wikiPageWikiLink Q18148801.
- Q424771 wikiPageWikiLink Q19484.
- Q424771 wikiPageWikiLink Q204711.
- Q424771 wikiPageWikiLink Q20970208.
- Q424771 wikiPageWikiLink Q21163221.
- Q424771 wikiPageWikiLink Q212322.
- Q424771 wikiPageWikiLink Q2985424.
- Q424771 wikiPageWikiLink Q3025883.
- Q424771 wikiPageWikiLink Q3520756.
- Q424771 wikiPageWikiLink Q411114.
- Q424771 wikiPageWikiLink Q417765.
- Q424771 wikiPageWikiLink Q418776.
- Q424771 wikiPageWikiLink Q419629.
- Q424771 wikiPageWikiLink Q420626.
- Q424771 wikiPageWikiLink Q424771.
- Q424771 wikiPageWikiLink Q425027.
- Q424771 wikiPageWikiLink Q464880.
- Q424771 wikiPageWikiLink Q467717.
- Q424771 wikiPageWikiLink Q470748.
- Q424771 wikiPageWikiLink Q4743610.
- Q424771 wikiPageWikiLink Q5120022.
- Q424771 wikiPageWikiLink Q529294.
- Q424771 wikiPageWikiLink Q546003.
- Q424771 wikiPageWikiLink Q564416.
- Q424771 wikiPageWikiLink Q575062.
- Q424771 wikiPageWikiLink Q582728.
- Q424771 wikiPageWikiLink Q6807295.
- Q424771 wikiPageWikiLink Q6973183.
- Q424771 wikiPageWikiLink Q7069573.
- Q424771 wikiPageWikiLink Q7145095.
- Q424771 wikiPageWikiLink Q7335370.
- Q424771 wikiPageWikiLink Q766195.
- Q424771 wikiPageWikiLink Q80726.
- Q424771 wikiPageWikiLink Q815382.
- Q424771 wikiPageWikiLink Q879952.
- Q424771 wikiPageWikiLink Q8965786.
- Q424771 wikiPageWikiLink Q927539.
- Q424771 wikiPageWikiLink Q9368.
- Q424771 wikiPageWikiLink Q9377.
- Q424771 atcPrefix "A10".
- Q424771 atcSuffix "BG02".
- Q424771 bioavailability "99.0".
- Q424771 casNumber "122320".
- Q424771 chebi "50122".
- Q424771 drugbank "DB00412".
- Q424771 iupacName "-5".
- Q424771 pubchem "77999".
- Q424771 unii "5".
- Q424771 type ChemicalSubstance.
- Q424771 type Drug.
- Q424771 type ChemicalObject.
- Q424771 type Thing.
- Q424771 type Q8386.
- Q424771 comment "Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride.".
- Q424771 label "Rosiglitazone".
- Q424771 depiction Rosiglitazone.svg.
- Q424771 homepage www.avandia.com.